BioLineRx Announces Plans to Launch ADR Program on NASDAQ
BioLineRx plans to list its shares through American Depositary Receipts (ADRs), to be traded on the NASDAQ under ticker "BLRX.”
View ArticleBioLineRx Announces First Subject Enrolled in Phase I Clinical Trial of...
This clinical trial will be a first-in-human, single-site, double-blind, placebo controlled study to assess safety, tolerability and pharmacokinetics of BL-1021 in healthy volunteers.
View ArticleBioLineRx Announces Positive Final Results from Phase Ia Clinical Trial of...
- BL-1021 was shown to be safe and well tolerated - - Safety is a significant concern in current neuropathic pain treatments -
View ArticleBioLineRx In-Licenses BL-7050, a Novel Orally Available Molecule for the...
BioLineRx has signed an agreement with Ramot, the technology transfer company of Tel Aviv University, for the development and commercialization of BL-7050, a novel, orally-available treatment for...
View ArticleBioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial...
Results show the drug is safe and well tolerated
View ArticleBioLineRx to Present Data from the Successfully Completed Phase IIb trial of...
BL-1020 is currently undergoing Phase II/III CLARITY clinical study
View ArticleBioLineRx Announces Receipt of Approval in India to Commence Phase II/III...
Trial results are expected in early 2013
View ArticleBioLineRx Reports Second Quarter 2011 Financial Results
Dr. Kinneret Savitsky, "During the second quarter we continued developing, advancing and enriching our pipeline, while focusing on products in advanced clinical stages"
View Article
